Screening for medium chain acyl-CoA dehydrogenase deficiency is being evaluatedBMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7293.1062 (Published 28 April 2001) Cite this as: BMJ 2001;322:1062
- Scott Grosse, health economist (firstname.lastname@example.org)
- Office of Planning, Evaluation, and Legislation, National Center for Environmental Health, US Centers for Disease Control and Prevention, Mail Stop F-29, Atlanta, GA 30341, USA
EDITOR—Tanner et al write that the effectiveness of screening neonates for medium chain acyl-CoA dehydrogenase deficiency has still not been completely evaluated.1 Evaluation of population based screening is a two part process. Firstly, the likely benefits and costs are assessed before the screening is introduced; and, secondly, an investigation is subsequently done into whether these calculations are borne out in practice.
The United Kingdom's health technology assessment process has undertaken the first step of its evaluation process …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial